503A vs 503B: A Med Spa Owner's Guide to Pharmacy Relationships

Clinic owners hear the terms 503A and 503B early, often in the first call with a pharmacy or a supply program. The numbers refer to two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Each section describes a different way a compounder can operate. Which one fills your order changes how you order, what paperwork you keep, and whether you can hold stock in the clinic.

This guide covers the operational side only. It explains the two categories in plain terms and lists the questions to ask before you set up a pharmacy relationship. Your medical director and your own healthcare counsel make the final decisions for your practice.

What a 503A pharmacy is

Section 503A applies to compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered with the FDA as an outsourcing facility. Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of these pharmacies. The FDA also conducts surveillance and for-cause inspections of them.

Compounding under section 503A must be based on a valid prescription for an identified individual patient. It can take place after the prescription is received, or in limited quantities before it is received, based on a history of receiving prescriptions for that preparation. FDA guidance states that section 503A does not provide for distributing a compounded drug product before a valid prescription for an identified individual patient is received.

If the pharmacy is in another state, ask which license or registration it holds for shipments into your state, and check it on your state board of pharmacy's website.

What this means for your clinic

• Each order starts with a prescription written by a licensed prescriber for a specific person.
• Shipping goes to that person or to the clinic, depending on state rules and the pharmacy's policy.
• Your records link each order to a prescription, a prescriber and a ship-to address.

What a 503B outsourcing facility is

Section 503B was added to the FD&C Act by the Drug Quality and Security Act, enacted on November 27, 2013. It created a voluntary category of compounders called outsourcing facilities. An outsourcing facility compounds sterile drugs (and may also compound non-sterile drugs), has registered with the FDA, and must meet all of the conditions of section 503B. It is not required to be a licensed pharmacy, but compounding must be done by or under the direct supervision of a licensed pharmacist.

Outsourcing facilities must comply with current good manufacturing practice (CGMP) requirements and are inspected by the FDA on a risk-based schedule. They report adverse events to the FDA. They also report the drugs they compounded when they first register and again in June and December each year.

An outsourcing facility may or may not obtain prescriptions for identified individual patients. It can distribute compounded drugs in response to an order from a health care provider that is not for an identified individual patient, for example office stock.

Registration means only that the FDA has received the information required to register the facility. It does not mean the facility makes FDA-approved drugs, and it does not mean the facility complies with CGMP requirements or the other conditions of section 503B.

The FDA publishes a list of registered outsourcing facilities on its website, including the date of each facility's last inspection. It also publishes compounding inspection, recall and warning letter documents. Both are public and free to check.

What this means for your clinic

• The clinic places an office-use order through its prescriber, without a prescription for each person.
• Product can be kept in the clinic, subject to the facility's terms and your state's rules.
• Availability depends on what the facility has in stock or scheduled, so ask about lead times.
• Section 503B requires certain information on the label and container, such as the statement “This is a compounded drug.”

What both categories have in common

Compounded drugs are not FDA-approved, whether they come from a 503A pharmacy or a 503B outsourcing facility. The FDA does not review them for safety, effectiveness or quality before they are marketed.

How the difference shows up day to day

The legal category sets the shape of your ordering workflow. Here is how the two compare on the tasks your front desk and practice manager handle.

What starts an order

For a 503A order, a prescription for a named person starts the process. For a 503B order, an office-use order from the clinic's prescriber starts it.

What sits on your shelf

With 503A, each fill belongs to a prescription for one named person, and section 503A does not provide for distribution before that prescription is received. With 503B, clinics can obtain products for office use and keep them on hand.

What paperwork you keep

Both routes generate order records, invoices, packing slips and lot numbers. A 503A order adds a prescription record. A 503B order adds the clinic's office-use order and the facility's batch information.

How you plan reorders

With 503A, you plan around individual prescriptions and pharmacy turnaround. With 503B, you plan around the facility's availability and your own par levels.

State rules sit on top of federal rules

Federal law sets the two categories. State pharmacy laws also apply, including rules on licensing, office use, shipping into the state, and who may receive a shipment. These rules differ from state to state and they change.

Federal and state guidance on which substances may be compounded also changes over time. A product that a pharmacy can fill today may become unavailable later. A good pharmacy relationship includes a clear process for telling you when that happens.

Before you build a program around any product, ask your healthcare counsel how your state handles office-use stock and shipments to individuals.

Questions to ask before you choose a pharmacy relationship

1. Which category fills each item? Ask whether the pharmacy is a 503A pharmacy, a 503B outsourcing facility, or whether the program uses both. Get the answer item by item.
2. Is it licensed for your state? Ask for the license or registration number that covers shipments into your state. Check it on your state board of pharmacy's website.
3. For a 503B, is it on the FDA list? Confirm the facility appears on the FDA's list of registered outsourcing facilities. Ask when its most recent inspection took place and how any observations were resolved.
4. Who signs orders, and where is that recorded? Every order needs a licensed prescriber. Ask how the system captures the prescriber's review and signature.
5. What comes with each shipment? Ask whether every shipment includes lot numbers, a certificate of analysis on request, and a beyond-use or expiration date on the label.
6. Can the clinic keep stock? Ask which items, if any, can be held as office-use stock in your state, and under which terms.
7. How are recalls and quality notices sent? Ask who receives them at your clinic, by what channel, and how quickly.
8. What happens when a product's status changes? Ask how the pharmacy or program tells clinics that an item is coming off the list, and what happens to open orders.

Write the answers down and file them in your vendor file. You will use them again at your annual vendor review. Our vendor checklist for med spas covers the rest of that review.

How Star Health handles this

Star Health is not a pharmacy and does not compound, store, or dispense medication. We connect med spas and medical practices with independently licensed pharmacies: state-licensed 503A pharmacies for patient-specific prescriptions and FDA-registered 503B outsourcing facilities for office-use stock.

Before portal access is activated, we confirm the prescriber's active state license and NPI. Every order requires the prescriber's signature. Every product on the formulary is reviewed against current federal and state compounding rules; when a substance's status changes, it is removed from the portal and open orders are reviewed. We do not supply research-use-only products. Lot numbers and order records are kept for every shipment. Read our full compliance overview, browse the formulary, or see the FAQ.

Sources

Federal statements in this article were checked against these FDA pages on October 17, 2026:

• FDA: Human Drug Compounding Laws
• FDA: FD&C Act Provisions that Apply to Human Drug Compounding
• FDA guidance: Prescription Requirement Under Section 503A of the FD&C Act (December 2016)
• FDA: Compounding and the FDA: Questions and Answers
• FDA: Information for Outsourcing Facilities
• FDA: Questions and Answers: Outsourcing Facility Registration
• FDA: Registered Outsourcing Facilities
• FDA: Compounding: Inspections, Recalls, and other Actions

This article is general business information for licensed practices. It is not medical, legal or regulatory advice. Your medical director and your own counsel make the decisions for your practice.